title: [Anti-VEGF therapy of neovascular age-related macular degeneration: therapeutic strategies status December 2012].
authors: Augenabteilung am St. Franziskus Hospital, Hohenzollernring 74, Münster. dapauleikhoff@muenster.de
authors: D
authors: D
authors: Pauleikhoff
authors: B
authors: B
authors: Bertram
authors: F G
authors: FG
authors: Holz
authors: B
authors: B
authors: Kirchhof
authors: U
authors: U
authors: Bartz-Schmidt
authors: N
authors: N
authors: Bornfeld
authors: M
authors: M
authors: Bresgen
authors: N
authors: N
authors: Eter
authors: W
authors: W
authors: Friedrichs
authors: H
authors: H
authors: Heimann
authors: H
authors: H
authors: Helbig
authors: H
authors: H
authors: Hörauf
authors: A
authors: A
authors: Kampik
authors: K D
authors: KD
authors: Lemmen
authors: J
authors: J
authors: Roider
authors: F
authors: F
authors: Ziemssen
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017277:Drug Approval; D005451:Fluorescein Angiography / Q000187:drug effects; D006801:Humans; D009887:Ophthalmoscopy; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000187:drug effects; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab